DCTH at a glance
DELCATH SYSTEMS, INC. (DCTH, SEC CIK 872912) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), DELCATH SYSTEMS, INC. (DCTH) reported revenue of $85.2 million (up 129.1% from FY2024) and net income of $2.7 million. Diluted EPS was $0.07.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding DELCATH SYSTEMS, INC. (DCTH) shares worth $148.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Martell Bridget A on November 12, 2026 of 1,930 shares at $22.26 per share.
- In the last 90 days, DCTH insiders reported 0 open-market purchases ($0) and 2 open-market sales ($489K) on Form 4, a net sale of $489K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $85.2M
- +129.1% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$489K
- 13F holders
- 24 funds
- $148.7M · +1 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $35.1M, up $14.5M YoY from $20.6M, driven by HEPZATO commercial expansion
- Operating margin 20.3% vs negative 1.9% YoY, operating income $7.1M vs $(0.4)M
- Best performer HEPZATO KIT: $32.7M revenue vs $19.3M, CHEMOSAT $2.4M vs $1.3M
- Operating cash flow $14.7M vs $14.3M YoY, cash and equivalents $55.5M plus investments $48.8M
- Outlook: liquidity expected to fund operations at least 12 months, Phase 2 trial expenses expected to increase
Risk Factors
- No material changes from the Annual Report, with business, financial condition, and results of operations exposed to disclosed risks
- Unknown or currently immaterial risks could significantly impair operations, financial condition, or results
- Common-stock market price could decline, potentially causing investors to lose all or part of their investment
AI summary of the DCTH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Delcath announced third-quarter 2026 financial results and business highlights for the quarter ended September 30, 2026
- Exhibit 99.1 contains the substantive results and operating update investors should review
Item EX-99.1: Item EX-99.1
- Q3 revenue $35.1M, up from $20.6M, led by HEPZATO revenue of $32.7M
- Net income $7.0M versus $0.8M, with adjusted EBITDA $11.5M versus $5.3M
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Bylaws amended August 12, 2026, effective immediately, by board action
- Delaware Chancery Court designated exclusive forum for internal corporate claims
Item EX-99.1: Item EX-99.1
- Q2 revenue rose to $29.1M from $24.2M, led by HEPZATO KIT revenue of $27.1M
- Gross margin expanded to 90% from 86%, supporting strong product economics
Item 2.02: Results of Operations and Financial Condition
- Press release announces Delcath’s financial results for the quarter ended June 30, 2026
- Business highlights accompany the quarterly results, with details contained in Exhibit 99.1
AI summaries of DCTH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DCTH
Don't miss the next DCTH filing
- Alerts as it files. A push when DCTH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DCTH, by share count.
- Ask anything. An AI agent that reads every DCTH filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Martell Bridget A | M | Nov 12, 2026 | 22,500 | $7.85 |
| Martell Bridget A | M | Nov 12, 2026 | 22,500 | - |
| Martell Bridget A | Sell | Nov 12, 2026 | 1,930 | $22.26 |
| Martell Bridget A | Sell | Nov 12, 2026 | 20,570 | $21.66 |
| Rosalind Advisors, Inc. | J | Oct 13, 2026 | 27,502 | - |
| Rosalind Advisors, Inc. | C | Oct 13, 2026 | 3,627 | - |
| Rosalind Advisors, Inc. | C | Oct 13, 2026 | 36.27 | - |
| Sylvester John Richard | A | May 13, 2026 | 22,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $37.2M | $85.2M |
| Gross Profit | - | $31.0M | $73.4M |
| Operating Income | - | -$12.4M | $660K |
| Net Income | - | -$26.4M | $2.7M |
| Gross Margin | - | 83.4% | 86.2% |
| Op. Margin | - | -33.4% | 0.8% |
| Net Margin | - | -70.9% | 3.2% |
| Balance Sheet | |||
| Total Assets | $38.6M | $76.6M | $123.6M |
| Equity | - | $68.7M | $111.2M |
| ROE | - | -38.4% | 2.4% |
| Per Share | |||
| EPS | - | $-0.93 | $0.07 |
| Cash Flow | |||
| Operating CF | - | -$18.7M | $22.5M |
| CapEx | $58K | $559K | $1.5M |
Source: XBRL data in DELCATH SYSTEMS, INC. (DCTH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate DCTH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $148.7M |
| Q2 2026 | 23 | $88.3M |
| Q1 2026 | 21 | $55.5M |
| Q4 2025 | 19 | $66.9M |
| Q3 2025 | 21 | $68.1M |
| Q2 2025 | 21 | $93.6M |
| Q1 2025 | 13 | $44.4M |
| Q4 2024 | 9 | $28.3M |
- BlackRock+1.29M (+48%)
- Morgan Stanley+142.6K (+35%)
- Vanguard Portfolio Management LLC+141.7K (+73%)
- JPMorgan Chase & Co+137.5K (+1063%)
- Goldman Sachs Group+118.5K (+47%)
- Wells Fargo & Co−19.0K (-67%)
- D.E. Shaw & Co−12.9K (-22%)
- Northern Trust−3.3K (-1%)
- Invesco Ltd−877 (-5%)
- U.S. Bancorp−92 (-88%)
- Ameriprise Financial+95.1K
- Franklin Resources+64.9K
- FMR LLC (Fidelity)−5.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 151 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DCTH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 13, 2026 | - | - | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Oct 14, 2026 | - | - | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| SC 13G | Jul 28, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Mar 20, 2026 | - | - | |
| 4 | Mar 6, 2026 | - | - | - |
| 8-K | Mar 3, 2026 | - | Analysis | - |
| 4 | Mar 3, 2026 | - | - | - |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
| 4 | Feb 18, 2026 | - | - | |
| 4 | Feb 18, 2026 | - | - | |
| 4 | Feb 18, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
DCTH SEC filings: frequently asked questions
Are DCTH insiders buying or selling?
In the last 90 days, DELCATH SYSTEMS, INC. (DCTH) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $488,508 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold DCTH stock?
As of September 30, 2026, the largest DELCATH SYSTEMS, INC. (DCTH) holders among the 13F filers tracked by SignalX were BlackRock ($63.8 million), Vanguard Capital Management LLC ($19.6 million), State Street Corp ($12.1 million), Millennium Management ($9.7 million), Morgan Stanley ($8.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DCTH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), DELCATH SYSTEMS, INC. (DCTH) reported revenue of $85.2 million (up 129.1% from FY2024) and net income of $2.7 million. Diluted EPS was $0.07. The figures come from the XBRL data in the 10-K.
What did DCTH report in its latest 8-K?
DELCATH SYSTEMS, INC. (DCTH) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Delcath announced third-quarter 2026 financial results and business highlights for the quarter ended September 30, 2026.
What are the latest DCTH SEC filings?
DELCATH SYSTEMS, INC. (DCTH) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 13, 2026.
What is DCTH's SEC CIK number?
DELCATH SYSTEMS, INC. (DCTH)'s SEC Central Index Key (CIK) is 872912. EDGAR lists every DCTH filing under that number.
Ask anything about DCTH
The research agent reads DCTH's filings, financials, insider trades and 13F holders, then answers with sources.